Compugen’s Cancer Immunotherapy Program Targets TIGIT Immune Checkpoint
News
Compugen has revealed details of its cancer immunotherapy program for TIGIT – internally known as CGEN-15137 – an immune checkpoint that has recently gained attention from the immuno-oncology industry. TIGIT, a T-cell immune-receptor with Ig and ... Read more